Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2014Research and Reports in Endocrine DisordersOpen Access

Simvastatin/fenofibrate combination therapy was superior to statin monotherapy in modifying atherogenic dyslipidemia, but cardiovascular endpoints were not significantly different in randomized clinical trials, except in subgroups with high triglycerides and low HDL.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does simvastatin/fenofibrate combination therapy reduce cardiovascular complications in patients with dyslipidemia compared to statin monotherapy?

Population

Patients with dyslipidemia and multiple cardiovascular risk

Comparison

Simvastatin/fenofibrate combination therapy vs Statin monotherapy

Design

Review

Authors

JJJose G. JimenezGHGregory Haft

Discussion

Loading...

Member takes

Overview

Combination therapy lacks support for cardiovascular benefit; leaves open targeted effects in high-triglyceride/low-HDL subgroups for prospective trials.

Structured PICO

Does simvastatin/fenofibrate combination therapy reduce cardiovascular complications in patients with dyslipidemia compared to statin monotherapy?

P
Population
Patients with dyslipidemia and multiple cardiovascular risk
I
Intervention
Simvastatin/fenofibrate combination therapy
C
Comparator
Statin monotherapy (standard low-density lipoprotein cholesterol reducing therapy)
O
Outcome
Cardiovascular complications/endpointshard clinical

Simvastatin/fenofibrate combination therapy improves lipid profiles compared to statin monotherapy but lacks evidence for reducing hard cardiovascular endpoints, except potentially in patients with high triglycerides and low HDL.

Limitations

  • Inclusion of heterogeneous populations in the analyzed studies

Cite This Study

Jimenez et al. (2014) studied this question.

synapsesocial.com/papers/6a70da82a7fbea1e44083bf2https://doi.org/10.2147/rred.s50952
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response2008 · 517 citations
  2. 2Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome2007 · 119 citations
  3. 3Coronary Artery Disease Risk in Familial Combined Hyperlipidemia and Familial Hypertriglyceridemia2003 · 208 citations
  4. 4EUROPEAN GUIDELINES ON CARDIOVASCULAR DISEASE PREVENTION IN CLINICAL PRACTICE2005 · 1,269 citations